This Article Full Text Full Text (PDF) Supplementary Data Correction (v67,p12034) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antony, S. Articles by Pommier, Y. Search for Related Content PubMed PubMed Citation Articles by Antony, S. Articles by Pommier, Y.

Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance

¹ Laboratory of Molecular Pharmacology and ² Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland and ³ Department of Medicinal Chemistry and Molecular Pharmacology, and the Purdue Cancer Center, Purdue University, West Lafayette, Indiana

Requests for reprints: Yves Pommier, Laboratory of Molecular Pharmacology, National Cancer Institute, 37 Convent Drive, Building 37, Room 5068, NIH, Bethesda, MD 20892-4255. Phone: 301-496-5944; Fax: 301-402-0752; E-mail: pommier{at}nih.gov.

Camptothecin (CPT) derivatives are effective anticancer drugs, especially against solid tumors. As CPTs are chemically unstable and have clinical limitations, we have synthesized indenoisoquinolines as novel topoisomerase I (Top1) inhibitors. We presently report two indenoisoquinoline derivatives, NSC 725776 and NSC 724998, which have been selected for therapeutic development. Both are potent Top1 inhibitors and induce Top1 cleavage at unique genomic positions compared with CPT. Consistent with Top1 poisoning, protein-linked DNA breaks were detected in cells treated with NSC 725776 and NSC 724998 at nanomolar concentrations. Those drug-induced protein-linked DNA breaks persisted longer after drug removal than those produced by CPT. Studies in human cells in culture show that NSC 725776 and NSC 724998 exert antiproliferative activity at submicromolar concentrations. Furthermore, NSC 725776 and NSC 724998 show cross-resistance in cells deficient or silenced for Top1, which is consistent with their selective Top1 targeting. Similar to other known Top1 inhibitors, NSC 725776–treated and NSC 724998–treated cells show an arrest of cell cycle progression in both S and G₂-M and a dependence on functional p53 for their cytotoxicity. Dose-dependent -H2AX foci formation was readily observed in cells treated with NSC 725776 and NSC 724998. These -H2AX foci were detectable at pharmacologically relevant doses for up to 24 h and thus could be used as biomarkers for clinical trials (phase 0). [Cancer Res 2007;67(21):10397–405]

This article has been cited by other articles:

				M. Li, Z.-H. Miao, Z. Chen, Q. Chen, M. Gui, L.-P. Lin, P. Sun, Y.-H. Yi, and J. Ding Echinoside A, a new marine-derived anticancer saponin, targets topoisomerase2{alpha} by unique interference with its DNA binding and catalytic cycle Ann. Onc., September 22, 2009; (2009) mdp335v1. [Abstract] [Full Text] [PDF]

				Y.-W. Zhang, T. L. Jones, S. E. Martin, N. J. Caplen, and Y. Pommier Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response J. Biol. Chem., July 3, 2009; 284(27): 18085 - 18095. [Abstract] [Full Text] [PDF]

				T. D. Pfister, W. C. Reinhold, K. Agama, S. Gupta, S. A. Khin, R. J. Kinders, R. E. Parchment, J. E. Tomaszewski, J. H. Doroshow, and Y. Pommier Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity Mol. Cancer Ther., July 1, 2009; 8(7): 1878 - 1884. [Abstract] [Full Text] [PDF]

				J. Guirouilh-Barbat, S. Antony, and Y. Pommier Zalypsis (PM00104) is a potent inducer of {gamma}-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition Mol. Cancer Ther., July 1, 2009; 8(7): 2007 - 2014. [Abstract] [Full Text] [PDF]

				J. Guirouilh-Barbat, Y.-W. Zhang, and Y. Pommier Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin Mol. Cancer Ther., July 1, 2009; 8(7): 1985 - 1994. [Abstract] [Full Text] [PDF]

				Y. Pommier and M. Cushman The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives Mol. Cancer Ther., May 1, 2009; 8(5): 1008 - 1014. [Abstract] [Full Text] [PDF]

				R. P. Bakshi, D. Sang, A. Morrell, M. Cushman, and T. A. Shapiro Activity of Indenoisoquinolines against African Trypanosomes Antimicrob. Agents Chemother., January 1, 2009; 53(1): 123 - 128. [Abstract] [Full Text] [PDF]

				C. Pisano, M. De Cesare, G. L. Beretta, V. Zuco, G. Pratesi, S. Penco, L. Vesci, R. Fodera, F. F. Ferrara, M. B. Guglielmi, et al. Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968 Mol. Cancer Ther., July 1, 2008; 7(7): 2051 - 2059. [Abstract] [Full Text] [PDF]

				Correction: Topoisomerase I Inhibition by NSC 725776 and NSC 724998 Cancer Res., December 15, 2007; 67(24): 12034 - 12034. [Full Text] [PDF]